DR ANINDYA MUKHERJEE

Senior Consultant,Medical Oncologist

Shardacare Healthcity, Noida - 201310

The phase III DELII trial (Development of Low-Dose Immunotherapy in India) reports that ultra–low-dose nivolumab significantly improves overall survival compared with chemotherapy in patients with relapsed or refractory solid tumors challenging long-standing assumptions regarding dose intensity in immuno-oncology.

Study Rationale

Pharmacodynamic data have demonstrated early PD-1 receptor saturation (~70% at 0.1 mg/kg), with a plateau in efficacy beyond lower doses. Investigators therefore examined whether a substantially reduced fixed dose of nivolumab could preserve clinical benefit while improving affordability and access particularly in resource-constrained settings.

Study Design

DELII was a randomized, open-label, phase III superiority trial conducted across India. The study enrolled 500 patients with ECOG performance status 0–1 and at least one prior systemic therapy for advanced solid tumors.

Participants were randomly assigned to receive:

• Nivolumab 20 mg intravenously every 2 weeks
• Physician’s choice chemotherapy (docetaxel or paclitaxel)

The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), safety, and quality of life.

Efficacy Outcomes

At a median follow-up of 28 months, the trial met its primary endpoint:

• Median OS:
  1. 5.88 months with nivolumab
  2. 4.70 months with chemotherapy
• Hazard ratio: 0.80 (95% CI, 0.66–0.97; P = .022)
• 20% reduction in the risk of death
• 1-year OS: 27.3% vs 16.9%, respectively

PFS was similar between arms (~2 months), and ORR did not significantly differ consistent with the delayed survival benefit characteristic of immune checkpoint inhibitors.

Safety and Quality of Life

Grade ≥3 adverse events occurred less frequently with ultra–low-dose nivolumab compared with chemotherapy (42.5% vs 60.8%; P < .001). Quality-of-life measures favored nivolumab.

Clinical Implications

DELII provides level I evidence that meaningful survival benefit with PD-1 blockade can be achieved at a fraction of the conventional dose. The findings challenge the traditional “maximum tolerated dose” paradigm and suggest that immunotherapy efficacy may be driven more by tumor immune biology than by dose escalation.
In the Indian context and more broadly across low- and middle-income countries these data carry substantial implications. While biosimilars reduce cost per milligram, dose de-escalation reduces total drug consumption and wastage, potentially improving cost-effectiveness and access.
DELII may inform future dosing strategies, reimbursement frameworks, and guideline discussions in settings where affordability remains a major determinant of treatment availability.
Further study may clarify whether dose optimization strategies can be extended across tumor types and other checkpoint inhibitors, advancing a more value-conscious approach to global oncology care.